2-氨基-4-氰基苯甲酸甲酯 | 159847-83-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氨基-4-氰基苯甲酸甲酯
• 中文别名: 苯甲酸,2-氨基-4-氰基-,甲基酯
• 英文名称: methyl 2-amino-4-cyanobenzoate
• 英文别名: 2-Amino-4-cyano-benzoic acid methyl ester
• CAS: 159847-83-3
• 化学式: C₉H₈N₂O₂
• 分子量: 176.175
• InChiKey: VCYAYJCEAKQYAM-UHFFFAOYSA-N

物化性质

• 沸点：
  357.9±27.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  76.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2926909090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

反应信息

• 作为反应物：
  描述：

  2-氨基-4-氰基苯甲酸甲酯 在 N,N-二异丙基乙胺 吡啶 、 盐酸 、 sodium hydroxide 、 ammonium chloride 、 sodium hydride 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 sodium nitrite 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 31.0h， 生成 4-cyano-2-{[(5-isopropyl-3,4-dimethyl-1,3-thiazol-2(3H)-ylidene)amino]sulfonyl}benzamide
  参考文献：
  名称：

  Studies of non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: Synthesis and structure–activity relationships of 2-cyano and 2-hydroxy thiazolidenebenzenesulfonamide derivatives

  摘要：

  In a previous study, we described the structure-activity relationships (SARs) for a series of thiazolidenebenzenesulfonamide derivatives. These compounds were found to be highly potent inhibitors of the wild type (WT) and Y181C mutant reverse transcriptases (RTs) and modest inhibitors of K 103N RT. These molecules are thus considered to be a novel class of non-nucleoside HIV-1 RT inhibitors (NNRTIs). In this paper, we have examined the effects of substituents on both the thiazolidene and benzenesulfonamide moieties. Introduction of a 2-cyanophenyl ring into these moieties significantly enhanced anti-HIV-1 activity, whereas a 2-hydroxyphenyl group endowed potent activity against RTs, including K103N and Y181C mutants. Among the series of molecules examined, 101 and 18b (YM-228855), combinations of 2-cyanophenyl and 4-methyl-5-isopropylthiazole moieties, showed extremely potent anti-HIV-1 activity. The EC50 values of 101 and 18b were 0.0017 and 0.0018 muM, respectively. These values were lower than that of efavirenz (3). Compound 11g (YM-215389), a combination of 2-hydroxyphenyl and 4-chloro-5-isopropylthiazole moieties, proved to be the most active against both K103N and Y181C RTs with IC50 values of 0.043 and 0.013 muM, respectively. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.11.045
• 作为产物：
  描述：

  2,5-二溴苯胺 在 盐酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 135.0h， 生成 2-氨基-4-氰基苯甲酸甲酯
  参考文献：
  名称：

  Crosby, John; Moilliet, Jock; Parratt, Julian S., Journal of the Chemical Society. Perkin transactions I, 1994, # 13, p. 1679 - 1688

  摘要：

  DOI：

文献信息

• 3-Acyl-4-hydroxyquinolin-2(1H)-ones. Systemically active anticonvulsants acting by antagonism at the glycine site of the N-methyl-D-aspartate receptor complex
  作者：Michael Rowley、Paul D. Leeson、Graeme I. Stevenson、Angela M. Moseley、Ian Stansfield、Ian Sanderson、Lesley Robinson、Raymond Baker、John A. Kemp

  DOI：10.1021/jm00074a020

  日期：1993.10

  receptor contain a carboxylic acid, which we believe to be detrimental to penetration of the blood-brain barrier. By consideration of a pharmacophore, novel antagonists at this site have been designed in which the anionic functionality is a vinylogous acid, in the form of a 4-hydroxyquinolin-2(1H)-one. In this series, a 3-substituent is necessary for binding, and correct manipulation of this group leads

  NMDA受体的甘氨酸位点上的大多数完全拮抗剂都包含一种羧酸，我们认为这对血脑屏障的渗透是有害的。通过考虑药效基团，已经设计了该位点的新型拮抗剂，其中阴离子官能团是4-羟基喹啉-2（1H）-一形式的乙烯基次糖基酸。在该系列中，结合需要使用3个取代基，并且对该基团的正确操作会导致生成化合物，例如3-（3-羟苯基）炔丙基酯24（L-701,273），其IC50取代[3H] -L-689,560在1.39 microM的皮质切片中结合0.17 microM和Kb与NMDA结合。测试化合物在DBA / 2小鼠中预防音源性癫痫发作的能力。该系列中最有效的化合物是环丙基酮42（L-701,252），ED50为4。1 mg / kg腹腔注射。提出了与甘氨酸位点结合的模型，其中重要的相互作用是推定的受体阳离子与3-取代基的pi-系统。
• FUROISOQUINOLINE DERIVATIVE AND USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1541576A1

  公开（公告）日：2005-06-15

  The present invention provides a compound represented by the formula    wherein A represents (1) a bond, (2) a group represented by the formula -CRa=CRb- (Ra and Rb each represent a hydrogen atom or C1-6 alkyl) and the like; R1 represents (1) cyano or (2) an optionally esterified or amidated carboxyl group; R2 represents (1) a hydrogen atom, (2) an optionally substituted hydroxy group, (3) an optionally substituted amino group and the like; R3 and R4 each represent a hydrogen atom and the like; R5 represents a hydrogen atom and the like; R6 represents an optionally substituted hydroxy group and the like; R7and R8 each represent an optionally substituted hydrocarbon group and the like; R9 and R10 each represent (1) a hydrogen atom and the like; Y represents an optionally substituted methylene group; and n represents 0 or 1, or a salt thereof, which has an excellent phosphodiesterase IV inhibiting action.

  本发明提供了一种化合物，其表示为式中的化合物，其中A代表（1）键，（2）由式 -CRa=CRb-（Ra和Rb分别代表氢原子或C1-6烷基等）表示的基团等；R1代表（1）氰基或（2）可选择酯化或酰胺化的羧基；R2代表（1）氢原子，（2）可选择取代的羟基，（3）可选择取代的氨基等；R3和R4各自代表氢原子等；R5代表氢原子等；R6代表可选择取代的羟基等；R7和R8各自代表可选择取代的碳氢基团等；R9和R10各自代表（1）氢原子等；Y代表可选择取代的亚甲基基团；n代表0或1，或其盐，具有优异的磷酸二酯酶IV抑制作用。
• Optimizing TRPM4 inhibitors in the MHFP6 chemical space
  作者：Clémence Delalande、Mahendra Awale、Matthias Rubin、Daniel Probst、Lijo C. Ozhathil、Jürg Gertsch、Hugues Abriel、Jean-Louis Reymond

  DOI：10.1016/j.ejmech.2019.01.048

  日期：2019.3

  We recently reported 4-chloro-2-(2-chlorophenoxy)acetamido)benzoic acid (CBA) as the first potent inhibitor of TRPM4, a cation channel implicated in cardiac diseases and prostate cancer. Herein we report a structure-activity relationship (SAR) study of CBA resulting in two new potent analogs. To design and interpret our SAR we used interactive color-coded 3D-maps representing similarities between compounds

  我们最近报道了4-氯-2-（2-氯苯氧基）乙酰氨基）苯甲酸（CBA）作为TRPM4的第一种有效抑制剂，TRPM4是一种涉及心脏病和前列腺癌的阳离子通道。本文中，我们报告了CBA的结构-活性关系（SAR）研究，得出了两个新的有效类似物。为了设计和解释我们的SAR，我们使用了交互式彩色编码3D图，这些图代表了用MHFP6（MinHash指纹最多可形成6个键）计算出的化合物之间的相似性，这是一种在基准虚拟筛选研究中优于其他指纹的新分子指纹。我们通过从与诱饵分子和药物有关的基准测试集中观察活性化合物的结构多样性，进一步说明了我们方法的一般适用性。MHFP6化学空间3D地图通常可能有助于设计，解释和传达SAR研究的结果。修改后的WebMolCS可从http://gdb.unibe.ch访问，代码可在https://github.com/reymond-group/webMolCS脱机使用。
• Quinoxaline compounds
  申请人：Allison D. Brett

  公开号：US20050038032A1

  公开（公告）日：2005-02-17

  Certain amidophenyl-sulfonylamino-quinoxaline compounds are CCK2 modulators useful in the treatment of CCK2 mediated diseases.

  某些氨基苯磺酰胺基喹喔啉化合物是CCK2调节剂，可用于治疗CCK2介导的疾病。
• Iminooxazolidine Derivatives and Their Use
  申请人：Rohrig Susanne

  公开号：US20100004292A1

  公开（公告）日：2010-01-07

  The present application relates to novel iminooxazolidine derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular thromboembolic disorders.

  本申请涉及新型亚胺噁唑啉衍生物，其制备方法，其用于治疗和/或预防疾病的用途，以及其用于制备治疗和/或预防疾病的药物，特别是血栓栓塞性疾病。